Summary Isolated limb perfusion (ILP) with tumour necrosis factor alpha (TNF-a) and melphalan has shown impressive results in patients with irresectable soft tissue sarcomas and stage III melanoma of the extremities. The mechanisms of the reported in vivo synergistic anti-tumour effects of TNF-a and melphalan are not precisely understood. We have developed an ILP model in the rat using a non-immunogenic sarcoma in which similar in vivo synergy is observed. The aim of this present study was to analyse the morphological substrate for this synergistic response of TNF-cx in combination with melphalan to shed more light on the pathomechanisms involved. Histology of the tumours from saline-(n = 14) and melphalan-treated (n = 11) rats revealed apparently vital tumour cells in over 80% of the cross-sections. Interstitial oedema and coagulation necrosis were observed in the remaining part of the tumour. Haemorrhage was virtually absent. TNF-oa (n = 22) induced marked oedema, hyperaemia, vascular congestion, extravasation of erythrocytes and haemorrhagic necrosis (20-60% of the cross-sections). Oedema and haemorrhage suggested drastic alterations of permeability and integrity of the microvasculature. Using light and electron-microscopy, we observed that haemorrhage preceded generalised platelet aggregation. Therefore, we suggest that the observed platelet aggregation was the result of the microvascular damage rather than its initiator. Remarkably, these events hardly influenced tumour growth. However, perfusion with the combination of TNF-a and melphalan (n = 24) showed more extensive haemorrhagic necrosis (80 -90% of the cross-sections) and revealed a prolonged remission (mean 11 days) in comparison with the other groups of rats. Electron microscopical analysis revealed similar findings as described after TNF-ax alone, although the effects were more prominent at all time points after perfusion. In conclusion, our findings suggest that the enhanced anti-tumour effect after the combination of TNF-a with melphalan results from potentiation of the TNF-oa-induced vascular changes accompanied by increased vascular permeability and platelet aggregation. This may result in additive cytotoxicity or inhibition of growth of residual tumour cells.
Isolated limb perfusion (ILP) with TNF-a and melphalan has shown impressive results in patients with irresectable soft tissue sarcomas and stage III melanoma of the extremities (Lienard et al., 1992 . ILP involves isolation of the diseased limb, its connection to a heart-lung machine and the administration of a triple drug regimen at 39-40°C (mild hyperthermia) based on the reported synergism of TNF-a with melphalan and interferon-y (IFN-y) (Eggermont et al., 1993) . The rationale of ILP is to improve the response rate by increasing the drug concentration while avoiding systemic toxicity. Morphological and immunohistochemical analysis of biopsies from patients after ILP suggested that the tumour microvasculature is a major target for TNF-a and melphalan. We and others have shown previously that events such as von Willebrand factor release, platelet aggregation and congestion concentrated on the tumour vasculature, leaving the normal tissues largely unaffected (Renard et al., 1994 (Renard et al., , 1995 . However, the mechanisms of in vivo synergistic anti-tumour effects of TNF-ax and melphalan are still not understood precisely.
As the drug regimen in patients contains at least two experimental drugs, it does not allow us to reach definitive conclusions about the relative contribution of TNF-a and melphalan. Therefore, an experimental isolated perfusion model on sarcoma in the rat was devised. Rats transplanted with a non-immunogenic BN sarcoma in the hind leg were treated by isolated limb perfusion (Marquet et al., 1983; Benckhuijsen et al., 1982; Manusama et al., 1994) . Using this model, we recently showed in vivo synergism between TNF-a and melphalan in ILP with a tumour response resembling the clinical results (Manusama et al., 1996) . ILP in the rat with saline or 50 ,ug of TNF-ax alone had no impact on tumour growth, and 40 ,ug of melphalan only temporarily inhibited tumour growth. In the group perfused with the combination of both TNF-c and melphalan, complete regression occurred in 75% of the rats. The aim of the present work was to study in this rat model the histopathological changes after ILP with TNF-oc alone, melphalan alone and the combination of both drugs and so shed more light on the pathomechanisms involved. We hereby present evidence at the light and electron-microscopical level that the histopathological changes observed in the tumours after perfusion with TNFa alone were augmented by addition of the chemotherapeutic agent.
Materials and methods Animals
Male rats of the inbred BN strain, weighing 250-300 g, were obtained from Harlan-CPB (Austerlitz, The Netherlands). They were fed a standard laboratory diet (Hope Farms, Woerden, The Netherlands) and kept under standard laboratory conditions. The specific protocol was approvedTumour The spontaneous BN 175 sarcoma transplantable to BN rats was used (Marquet et al., 1983) . This BN 175 sarcoma is a rapidly growing and metastasising tumour. Immunogenicity of the tumour was determined by inoculating rats with tumour, excising the tumour, reinoculating the rats with the same tumour and measuring the percentage of rats that show tumour take. According to this method, described by Prehn and Main (1957) , BN 175 sarcoma is nonimmunogenic.
Isolated limb perfusion (ILP) The tumour model and perfusion procedure were described previously by Manusama et al. (1994 Manusama et al. ( , 1996 . Briefly, small fragments of BN 175 sarcoma (3-5 mm) were implanted in the right hind limb subcutaneously. Perfusion was performed in rats with established tumours with a mean diameter of 13.6+3.0 mm at 10.3+3.0 days after transplantation.
Hypnorm (10 mg ml-' fluanisone, 0.315 mg ml-' fentanylcitrate: Janssen Pharmaceutica, Tilburg, The Netherlands) was given i.v. for anaesthesia. A warm water mattress was applied around the leg to maintain the temperature of the leg at 38-39°C. The temperature of the leg was measured during the perfusion by a naked bead type K probe fixed with its tip at the convexity of the tumour and connected to a digital thermometer (Mera Benelux, Berkel-Enschot, The Netherlands (Manusama et al., 1994) . A washout was done at the end of the perfusion with 2.0 ml of oxygenated Haemaccel. The perfusion time was 30 min, including the washout. After the procedure, the femoral vessels of the perfused limb were ligated, which was allowed by restoration of the collateral circulation. In the BN rat, the presence of collateral circulation was demonstrated by a continuous venous return when the femoral artery was ligated. Furthermore, oxygen pressure in the tumour after ligation of the femoral vessels was equivalent to that before ligation as described in a previous study (Manusama et al., 1994) . and 24 h after perfusion with saline (n = 4), melphalan (n = 4), TNF-a (n = 6) and TNF-cx in combination with melphalan (n = 6). Cryostat sections (4 pm) were stained using a twostep immunoperoxidase procedure, as described previously , using MAb PLl-1/Er 21 (Baghus et al., 1989) directed against rat platelets, kindly provided by Dr E De Heer (University Hospital Leiden, Leiden, The Netherlands), and using PAb RaHu FVIII, recognising von Willebrand factor (VWF) from the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (CLB). As secondary antibodies, peroxidase-conjugated swine antirabbit Ig and rabbit anti-mouse Ig were used (Dako, 1:100), preabsorbed with 5% normal rat serum. The peroxidase label was visualised by incubation with 3-amino-9-ethylcarbazole as a substrate. The semiquantitative grading used was as follows: no change (o), sporadic event (±), focal event (+), generalised event (+ +).
Electron microscopy Small tissue fragments from the central and the peripheral part of the tumour were immediately fixed for 24 h in 2.5% glutaraldehyde with 0.1 mol sodium cacodylate. The material was post-fixed in 1% osmium sodium cacodylate buffer for 1 h at room temperature (RT), dehydrated and embedded in epon 812. One micron sections were cut and stained with toluidine blue for light microscopy. Ultrathin sections were cut with a diamond knife (Drukker, Cuijk, The Netherlands) on an ultramicrotome (Reichert Jung, Vienna, Austria). The ultrathin sections were contrasted for 15 min with uranyl 3%, followed by a 3 min treatment with lead citrate, and examined and photographed with a JEOL 1200 EX/II electron microscope (Tokyo, Japan) at 60 kV. The electron microscopical analysis focused on the microvascular changes.
Results

Histology
The semiquantitative assessment of tumour necrosis in a representative histological section after the different treatment modalities at various time points following the perfusion is shown in Figure 1 (Figure 2g and h). In three rats (out of 24), a moderate infiltration of the tumour by polymorphonuclear cells was observed (not shown). In addition, the epidermis overlying the area of central necrosis was necrotic (Figure 2g) . A rim of viable tumour cells persisted at the margins next to the dermis (Figure 2g and h) and seemed to be responsible for the outgrowth of the tumour over the subsequent days.
Immunohistochemistry PLI-I (platelets) The semiquantitative assessment of platelet aggregation in a representative histological section after various treatment modalities at various time points following perfusion is shown in Figure 3 . Sections of the saline-treated rats 4, 12 and 24 h after perfusion showed sporadic (±) intravascular PLI-I staining in the tumour (Figure 4a ). PLI-I staining 4, 12 and 24 h after melphalan treatment varied from sporadic (±) to focal (+) (Figure 4b ). PL1-1 staining in the vessels outside the tumour was sporadically observed. TNF-a-treated rats showed intravascular PLI-I staining focally (+) in the tumour 4 h after treatment (not shown). Generalised (+ +) PLl-I staining was observed 12 and 24 h after TNF-oa-perfusion (Figure 4c ). PLI-I staining was also observed in vessels adjacent to the tumour. Perfusion treatment with TNF-a in combination with melphalan showed intravascular PLI-I staining focally (+) in the tumour in sections 4 h after perfusion (not shown). In all sections 12 and 24 h after perfusion with TNF- Synergistic effects of TNF-a and melphalan PTGA Nooijen et al 1913 a in combination with melphalan, marked generalised (+ +) PLI-1 staining was observed (Figure 4d) , and also in vessels adjacent to the tumour (Figure 4e ). rHu FVIII (von Willebrand factor) We found that this antibody was not suitable for the analysis as possible leakage of von Willebrand factor by the endothelium after perfusion treatment in our animal model, as the intensity of the endothelial staining was low in combination with a diffuse background staining.
Electronmicroscopy
The tumours contained numerous small vessels. Intratumoral vessels at the periphery of the control tumours and after saline perfusion revealed a continuous endothelial cell lining, often surrounded by pericytes. Smooth muscle cells were only occasionally found. Centrally in the tumour, few degenerated endothelial cells were observed in areas with oedema and haemorrhage, suggestive of vascular leakage. These findings were not accompanied by a marked inflammatory cell infiltrate. Platelets were found adherent to the vessel wall. The ultrastructural findings after ILP with melphalan (40 ,ug) resembled those described after saline perfusion.
After perfusion with TNF-a (50 ,ug), marked intercellular oedema was seen. Increased haemorrhage, both centrally and at the periphery (2, 4 and 12 h after ILP), suggested vascular leakage (Figure 5b ). Intratumoral and peritumoral vessels showed marked erythrostasis (Figure 5a and 5f ). At the periphery of the tumours, the vessels loaded with erythrocytes revealed signs of endothelial cell degeneration, i.e. electron-lucent cytoplasm and swollen mitochondria (Figure 5a and c) . Extensive aggregation of platelets was observed both in the intratumoral vessels and just outside the tumour, but merely mural and not occlusive (Figure 5e ). Increased haemorrhage and intravascular platelet aggregation were observed 24 h after perfusion with TNF-a in the tumour, with disintegration of the endothelial cells (Figure  5d ), only in the tumour centre, with extensive oedema and tumour cell necrosis. These phenomena were not accompanied by a marked inflammatory cell infiltrate.
Ultrastructural analysis of sections after perfusions with TNF-ax and melphalan revealed similar findings as described after TNF-a alone, although the findings were more prominent at all time points after perfusion. Because of this similarity, only the ultrastructural changes after TNF-a are shown.
Discussion
Tumour necrosis factor-a (TNF-a) in combination with interferon-y (IFN-y) and melphalan in an isolated limb perfusion setting resulted in a high remission rate in patients with irresectable soft tissue sarcomas (Lienard et al., 1992; Eggermont et al., 1992 ). An overall response rate of 88% with a limb salvage of 87% was reported (Eggermont et al., 1993) . However, perfusion with TNF-a alone proved to be ineffective (Posner et al., 1994) . The mechanism of tumour regression by the combination of TNF-a and the chemotherapeutic agent melphalan, in vivo, is not precisely understood but was proposed to follow a dual targeting pathway (Lejeune, 1995; Renard et al., 1995) . The first target is represented by the tumour microvasculature. TNF-a was assumed to induce endothelial cell damage, leading to von Willebrand factor release (VWF). Released VWF may play a role in the adhesion between platelet and the damaged endothelium or the denuded vessel wall. As a consequence, the blood flow is impaired, leading to congestion and oedema. The second target is represented by the tumour cells themselves, which are increasingly subjected to the cytotoxic effects of melphalan in a hypoxic environment.
In order to study the impact of the individual drugs on a non-immunogenic MCA-102 murine sarcoma after TNF-a i.v. injection and closely resembled the effects described for endotoxin-induced histopathological features (van de Wiel et al., 1989; Kuper et al., 1985 Kuper et al., , 1986 . TNF-oa induced oedema, hyperaemia, vascular congestion, extravasation of erythrocytes and haemorrhagic necrosis (20-60%) (Regenass et al., 1987; MacPherson and North, 1986; Sato et al., 1986) . Remarkably, these events hardly influenced tumour diameter and tumour growth in our rat ILP model. Increased doses of only TNF-a did not lead to an increased anti-tumour effect; even with doses of 100 ,ug in all seven rats, progressive disease was observed (unpublished results). Furthermore, when using TNF-a intravenously in toxic doses, no effect on tumour growth was noted in the same model (unpublished results). Therefore, the combination with melphalan is necessary to obtain an effective anti-tumour response. On the other hand, at higher doses of melphalan alone, regression occurred with a gradual disappearance of the tumour without haemorrhagic necrosis (Manusama et al., 1996) . Combination with TNF-a lowered the effective dose of melphalan and introduced a vascular component into the mechanism of action, characterised by extensive haemorrhagic necrosis. Oedema and haemorrhage suggested dramatic alterations of permeability and integrity of microvascular endothelial cells. The cause of the vascular stasis and congestion is not clear, but it may be related to a direct cytotoxic effect of TNF-a on endothelial cells (Sato et al., 1986) . A direct toxic effect and activation of procoagulant activity in tumour endothelial cells with subsequent thrombus formation might be responsible for haemorrhagic necrosis (Gerlach et al., 1989; Watanabe et al., 1988; Nawroth et al., 1988; Shimomura et al., 1988) . Using light and electron microscopy, we observed, however, that haemorrhage preceded generalised platelet aggregation without fusion of platelets with endothelial cells (Grau et al., 1993) . Therefore, we suggest that the observed platelet aggregation was the result of the endothelial damage rather than the initiator. These findings are consistent with those observed in sequential biopsies of human lesions after ILP (Renard et al., 1995) . In most cases, the centre of the tumour seemed to be more vulnerable to the treatment than the periphery. Aberrant branching and twisting of the vasculature and abnormal high pressure in the interstitial matrix of the tumour centre, with pre-existing increased vascular permeability, may have led to an uneven distribution of the drugs and uneven distribution of the vascular changes observed (Jain, 1987a,b) . The vascular changes in the tumour margins, accompanied with stasis, may have contributed to a decreased blood flow out of the tumour with development of central haemorrhagic necrosis.
The anti-tumour activity and necrosis induced by the combination of intratumorally injected TNF-oa and IFN-y systemically were studied by de Kossodo et al. (1995) in a breast cancer xenograft model. Recent study in an experimental ILP model revealed almost similar findings using the combination of TNF-a and melphalan. Similar potentiation of the anti-tumour activity were observed, associated with vascular congestion and accumulation of platelets in areas of vascular damage. Whether polymorphonuclear leucocytes contributed to the vascular damage in our rat ILP model is not clear. A polymorphonuclear cell infiltrate in the tumour after perfusion with TNF-a and with the combination generally was not observed, whereas haemorrhage and necrosis were a consistent finding. The exact role of polymorphonuclear leucocytes in the antitumour effect needs to be analysed in future studies using perfusions of granulocytopenic rats. Although it is difficult to derive the dynamics of vascular damage and tumour regression from static images, our observations support the interpretation of Regenass et al. (1987) that the TNF-ainduced increase in permeability of the endothelial cells leads to increased blood viscosity. In this view, the decreasing tumour blood flow is further impaired by intravascular platelet aggregation, resulting in a sustained haemostasis and finally in haemorrhagic infarction. The increased vascular permeability together with a reduced blood flow out of the tumour may have led to increased intratumoral concentrations of melphalan or prolongation of its effect. Our findings indicate that it is important to measure the effects on vascular permeability. Experiments to determine vascular permeability changes and melphalan concentrations in the tumours are in progress.
Perfusion with the combination of TNF-c and melphalan increased both the occurrence and extent of the haemorrhagic necrosis. Necrosis was not confined to the tumour cells but also involved microvascular cells, both in the tumour and in the adjacent dermis. The potentiation of the TNF-ac-induced vascular effects by melphalan might be explained by additive cytotoxicity direct to the vascular endothelium (Regenass et al., 1987; Kachel and Martin, 1994; Alexander et al., 1987) and/or increased endothelial cell reactivity to platelets (Bertomen et al., 1990) . Our (histo)pathological findings support the proposition by Lejeune (1995) that the combination of TNF-a and melphalan works through a dual targeting system. In this view, the first target is represented by the tumour vasculature and the second one by the tumour cells themselves. However, the proposed granulocyte-mediated endothelial damage does not seem to be a conditio sine qua non and therefore should be studied further. In conclusion, our findings suggest that the enhanced antitumour effect after the combination of TNF-oa with melphalan results from potentiation of the TNF-oc-induced vascular changes accompanied by increased permeability. This may result in additive cytotoxicity or inhibition of growth of residual tumour cells.
